European Lung Cancer Congress | Conference

Osimertinib Plus Dato-DXd Shows Efficacy in Post-Osimertinib EGFR-Mutated Advanced NSCLC

April 9th 2025

Osimertinib plus Dato-DXd elicits responses in patients with EGFR-mutated advanced NSCLC who progressed on first-line osimertinib.

Daraxonrasib Generates Clinical Activity With Manageable Safety in RAS-Mutant NSCLC

April 8th 2025

Daraxonrasib was safe and active in the pretreated advanced non–small cell lung cancer harboring RAS mutations.

Savolitinib Plus Osimertinib Elicits Durable Responses in Pretreated EGFR-Mutated, MET+ Advanced NSCLC

April 7th 2025

Savolitinib plus osimertinib produced responses in pretreated MET-amplified or -overexpressed advanced non–small cell lung cancer harboring EGFR mutations.

Pembrolizumab Plus cCRT Elicits Durable Antitumor Activity in Unresectable Stage III NSCLC

April 1st 2025

Updated KEYNOTE-799 data continued to show robust activity with pembrolizumab plus concurrent chemoradiation in unresectable stage III NSCLC.

Osimertinib After Definitive Chemoradiation Is New SOC for Unresectable Stage III EGFR+ NSCLC

March 31st 2025

Longer-term outcomes from LAURA further support the benefit of osimertinib over placebo for patients with unresectable stage III EGFR-mutated NSCLC.

Frontline Fulzerasib Plus Cetuximab Elicits Deep, Durable Responses in KRAS G12C–Mutated NSCLC

March 28th 2025

Fulzerasib plus cetuximab elicited deep efficacy in patients with KRAS G12C–mutated NSCLC enrolled in the phase 2 KROCUS study.

Adagrasib Combo Continues to Show Efficacy in KRAS G12C–Mutated NSCLC and PD-L1 ≥50%

March 28th 2025

Adagrasib plus pembrolizumab continued to show promising efficacy in patients with KRAS G12C–mutated NSCLC and PD-L1 TPS of 50% or higher.

Frontline Amivantamab Plus Lazertinib Significantly Reduces Mortality in EGFR-Mutant Advanced NSCLC

March 27th 2025

Amivantamab plus lazertinib provides long-term survival benefit over osimertinib in EGFR-mutated advanced non–small cell lung cancer.

First-Line Anlotinib Plus Etoposide and Carboplatin Improves PFS in ES-SCLC

March 25th 2024

Anlotinib plus etoposide, carboplatin, and placebo improved PFS vs etoposide plus carboplatin and 2 placebos in first-line ES-SCLC.

Concurrent Durvalumab/CRT Does Not Confer Significant Survival Advantage in Unresectable Stage III NSCLC

March 25th 2024

Durvalumab/chemoradiation did not significantly improve survival vs chemoradiation alone in patients with unresectable non–small cell lung cancer.

Becotarug Plus Osimertinib Elicits Responses in EGFR Exon 20 Insertion+ NSCLC

March 21st 2024

Becotarug plus osimertinib elicited responses with manageable safety in patients with non–small cell lung cancer and EGFR exon 12 insertion mutations.

Amivantamab Plus Chemo Nearly Doubles Time to Treatment Discontinuation, Need for Subsequent Therapy in EGFR Exon 20+ NSCLC

March 20th 2024

Amivantamab plus chemotherapy extended the time to treatment discontinuation and subsequent therapy in EGFR exon 20 insertion–mutated NSCLC.

Exploratory Analysis Shows Perioperative Nivolumab Confers Benefit in Resectable NSCLC, Irrespective of Neoadjuvant Treatment Cycles

March 20th 2024

Perioperative nivolumab improved responses in resectable non–small cell lung cancer, irrespective of the number of neoadjuvant treatment cycles completed.

Second-Line Liposomal Irinotecan Fails to Improve OS, PFS Over Topotecan in SCLC

April 6th 2023

Single-agent liposomal irinotecan resulted in a similar median overall survival and progression-free survival to that achieved with topotecan in patients with small cell lung cancer that had progressed on or following frontline platinum-based chemotherapy.

Cemiplimab With or Without Chemotherapy Provides Long-Term Clinical Benefit in Locally Advanced NSCLC

April 5th 2023

First-line cemiplimab monotherapy or in combination with platinum-based chemotherapy conferred long-term clinical benefit to patients with unresectable, locally advanced non–small cell lung cancer who were ineligible for concurrent chemoradiation.

Adagrasib Induces 68% ORR in Subset of Patients With KRAS G12C–Mutated NSCLC

April 4th 2023

Adagrasib induced high overall response rates in patients with KRAS G12C–mutated non–small cell lung cancer who achieved at least 90% mutation allele frequency clearance.

Atezolizumab Following Neoadjuvant Atezolizumab and Resection Improves DFS in NSCLC

April 4th 2023

Data for adjuvant atezolizumab following neoadjuvant atezolizumab and resection demonstrated an improvement in disease-free survival and a trend toward improved overall survival in patients with resectable stage IB to IIIB non–small cell lung cancer compared with those who did not receive adjuvant atezolizumab.

Eftilagimod Alpha/Pembrolizumab Generates Antitumor Activity in PD-1–Resistant NSCLC

April 3rd 2023

Treatment with eftilagimod alpha plus pembrolizumab resulted in tumor shrinkage and a tolerable safety profile in patients with anti–PD-1/PD-L1–resistant non–small cell lung cancer.

Atezolizumab/Cabozantinib Fails to Elicit Benefit Over SOC in Second-line Metastatic NSCLC

April 2nd 2023

Second-line atezolizumab plus cabozantinib did not generate a clinical benefit over standard-of-care docetaxel in patients with metastatic non–small cell lung cancer previously treated with immune checkpoint inhibitors and chemotherapy.

Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC

April 1st 2023

The combination of tusamitamab ravtansine and pembrolizumab with or without chemotherapy generated responses and was well tolerated when used as first-line treatment for patients with CEACAM5-positive nonsquamous non–small cell lung cancer.